Smartleaf Asset Management
VRDN icon

Smartleaf Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Smartleaf Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.52K Hold
134
– – ﹤0.01% 2895
2026
Q1 		$2.48K Hold
134
– – ﹤0.01% 2901
2025
Q4 		$4.16K Buy
+134
New +$3.68K ﹤0.01% 2776

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fairmount Funds Management
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Smartleaf Asset Management's VRDN Position: Q2 2026 in Review

Smartleaf Asset Management held its Viridian Therapeutics (VRDN) position steady in Q2 2026 at 134 shares worth $2.52K. The position accounts for ﹤0.01% of the portfolio, ranked #2895.

Smartleaf Asset Management first reported a position in VRDN in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.16K in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Smartleaf Asset Management held 134 shares of Viridian Therapeutics worth $2.52K as of Q2 2026.
  • Smartleaf Asset Management left its Viridian Therapeutics share count unchanged in Q2 2026.
  • Viridian Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #2895 holding.
  • Smartleaf Asset Management first reported a position in Viridian Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Smartleaf Asset Management's Viridian Therapeutics position peaked at $4.16K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.